acetylated peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
SASP induces an unfolded protein response in the endoplasmic reticulum because of an accumulation of unfolded proteins, resulting in proteotoxic impairment of cell function. SASP cytokines can result in an inflamed stem cell niche, leading to stem cell exhaustion and impaired stem cell function. The pro-inflammatory environment generated by SASP factors accelerates the breakdown of extracellular matrix thereby worsening intervertebral disc degeneration (IVDD). AMPK/p53 senescence produces a completely different SASP than IL-1 (p16INK4a) senescence, which is primarily responsible for IVDD. In IVDD, SASP is secreted by nucleus pulposus and annulus fibrosus cells, resulting in extracellular matrix degradation and extracellular inflammation. Senomorphics, but not senolytics have been found to alleviate symptoms without eliminating senescent cells. SASP can either promote or inhibit cancer, depending on the SASP composition, notably including p53 status. Despite the fact that cellular senescence likely evolved as a means of protecting against cancer early in life, SASP promotes the development of late-life cancers. Cancer invasiveness is promoted primarily through the actions of the SASP factors metalloproteinase, chemokine, interleukin 6 (IL-6), and interleukin 8 (IL-8). In fact, SASP from senescent cells is associated with many aging-associated diseases, including not only cancer, but atherosclerosis and osteoarthritis. For this reason, senolytic therapy has been proposed as a generalized treatment for these and many other diseases.
==== Honeydew honey ==== Honeydew honey is made from bees taking direct secretions from trees such as pine, fir, chestnut, and oak or primarily honeydew, the sweet secretions of aphids or other plant-sap-sucking insects, to produce honey rather than from nectar. This honey has a much larger proportion of indigestibles than light floral honeys, thus causing dysentery to the bees. Honeydew honey has a stronger and less sweet flavor than nectar-based honey, and European countries have been the primary market for honeydew honey. In Greece, pine honey, a type of honeydew honey, constitutes 60–65% of honey production.
== Ecology == Bilberry plants can suffer from bilberry blight, caused by Phytophthora kernoviae. There have been severe outbreaks in Staffordshire, England. Bilberry is used as a food plant by the larvae of some Lepidoptera species.
Sources: en.wikipedia.org
The first advances in wound care in this era began with the work of Ignaz Philipp Semmelweis, a Hungarian obstetrician who discovered how hand washing and cleanliness in general in medical procedures prevents maternal deaths. Semmelweis's work was furthered by an English surgeon, Joseph Lister, who in 1860s began treating his surgical gauze with carbolic acid, known today as phenol, and subsequently dropped his surgical team's mortality rate by 45%. Building on the success of Lister's pretreated surgical gauze, Robert Wood Johnson I, co-founder of Johnson & Johnson, began in the 1890s producing gauze and wound dressings sterilized with dry heat, steam, and pressure. These innovations in wound-site dressings marked the first major steps forward in the field since the advances of the Egyptians and Greeks centuries earlier. In 1886, Ernst von Bergmann introduced heat sterilization of surgical instruments, which marked the beginning of aseptic surgery and significantly reduced the frequency of infections. Conrad Brunner did extensive research into wound management and experimentation with wound disinfection methods, publishing his comprehensive Erfahrungen und Studien über Wundinfektion und Wundbehandlung in 1898. That same year, Paul Leopold Friedrich introduced wound excision and experimentally showed that excision of open wounds substantially reduced the risk of infection. The next advances would arise from the development of polymer synthetics for wound dressings and the "rediscovery" of moist wound-site care protocols in the mid 20th century.
Alendronic acid or Alendronate, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone, which works by decreasing the activity of osteoclasts, the cells that break down bone. It is taken by mouth as the neutral sodium salt, alendronate sodium, but is absorbed as the active free drug alendronic acid. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes. Common side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux; though the rate of all side effects were found by the Fracture Intervention Trial, which followed 2,027 women with osteoporosis for three years, to be nearly identical to that of the placebo. The study further found that the risk of a serious upper gastrointestinal adverse event was 60% lower (p<0.01) for the drug versus the placebo. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid was first described in 1978 and approved for medical use in the United States in 1995 as alendronate sodium (Fosamax). It is available as a generic medication. In 2023, it was the 113th most commonly prescribed medication in the United States, with more than 5 million prescriptions.
== Research contributions == Esimone pioneered research in the use of recombinant viral vectors as surrogates for high-throughput antiviral screening studies, as well as on the use of indigenous medicinal plants as immunomodulators, vaccine adjuvants, and anti-infectives. The vector-based antiviral screening technique developed by Esimone between 2003 and 2005 in Germany significantly revolutionized high-throughput screening for anti-HIV compounds worldwide. In addition to this work, his research led to the discovery of new antimicrobial compounds—including antibacterial, antifungal, and antiviral agents—derived from endophytes, lichens, ferns, herbs, and spices. Esimone was instrumental in the isolation and characterization of resistance genes from clinical settings, abattoirs, and poultry, with a particular focus on extended-spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs) identified in the southeastern regions of Nigeria. His team became the first to demonstrate the presence of ESBL-producing bacteria harboring the CTXM-15 gene, which confers resistance to third-generation cephalosporins in Nigeria. Additionally, they were the first to identify MBL-producing bacteria containing the blaIMP-1 and blaVIM-1 genes within poultry and abattoirs in southeastern Nigeria. They also reported the increasing frequency of MBL-producing Klebsiella, Pseudomonas, and Escherichia species in the country.
Sources: en.wikipedia.org
== History == During 2008 and 2009, all non-U.S. foreign forces withdrew from Iraq. Withdrawal of all non-U.S. forces was complete by 31 July 2009. As of 1 January 2009, the Iraqi government became fully responsible, through its security ministries, for maintaining and providing security and rule of law for its populace. Furthermore, as of 28 June 2009, no foreign forces were stationed within any of Iraq's major cities. The United States decided after negotiations to cease combat operations, that is, patrolling, serving arrest warrants, route clearance, etc., within Iraq by 1 September 2010, and to transition to an advisory, training and assistance role. The changing mission entailed major troop reductions. Numbers dropped from 115,000 on 15 December 2009, to 50,000 by 1 September 2010, and to zero by 31 December 2011.
Shorter D-stem: To understand the role of the unusual long D-stem in tRNASec, artificial variants with shorter D-stems were put into E. coli. It turns out that these variants work faster than the standard version at regular temperatures but easily lose function at high temperatures. This suggests that the long D-stem evolved as an adaptation to high temperature. Removal of SelB and SECIS requirement: In 2013, a new kind of tRNA was artificially created by putting the acceptor stem and CUA anticodon of E. coli tRNASec on the backbone of E. coli tRNASer. This new tRNAUTu can be recognized by ordinary EF-Tu, removing the requirement for SelB and SECIS for elongation. However, about 40% of the insertions were serine instead of selenocystine, suggesting that SelA is not efficiently recognizing this tRNA. In 2014, directed evolution was used to greatly improve the ability of tRNAUTu to be recognized by SelA, achieving a version that results in no detected misincorporation of serine. This enables simple replacement of any residue by Sec in future protein engineering efforts. By 2018, the E. coli system has matured to be suitable for "industrial scale" production. In one case this was achieved by laborotaory evolution. In another case this was achieved by incorporating elements of allo-tRNAs. The tRNAUTu system was adapted to Saccharomyces cerevisiae (yeast), which has no natural selenocystine system, in 2023. A mixture of bacterial and mouse enzymes work on a modified yeast tRNASer, which is able to be recognized by eEF1A.
== Content == The Code contains both mandatory regulations and recommended provisions, setting out the minimum stability standards for ships. This includes information on precautions against capsizing, metacentric heights (GM), righting levers (GZ), rolling criteria, Free surface effect and watertight integrity. The 2008 version of the Code details guidelines on Second Generation Intact Stability for ships, specifically criteria for dynamic stability and damage assessment. The Code is split into two parts. Part A contains mandatory criteria. Part B contains additional guidelines and recommendations. The Code requires each ship to have a stability book on the ship. For passenger ships, a regular survey is required.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.